March 30th, 2022Pivotal employees have shown to be very motivated and active again to participate in the race against Cancer held…
November 26th, 2021We would like to wish you a Merry Christmas and a Happy New Year as well as to thank…
November 17th, 2021The Insights Care Magazine recently interviewed Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s journey and…
July 8th, 2021The Pharma Tech Outlook magazine spoke recently with Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s overview…
June 10th, 2021The Silicon Review magazine spoke recently with Dr. Ibrahim Farr, Chairman & CEO at Pivotal, about the company’s main…
March 2th, 2021Madrid, Spain, 2 March, 2021 – Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, and Pivotal, a Europe-wide full-service…
January 18th, 2021We are very excited to announce the launch of our newly designed website. Our goal with this new website…
November 3th, 2020Global trial has recently expanded to Western Europe with the first European sites now initiated Collaboration will enable patients in…
October 21th, 2020Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in patients with liver metastasis from colorectal or…
September 3th, 2020We have deployed Azure DevOps Software as a Service It has been validated in compliance with 21 CFR part 11 to…